Donate to CASPR

Strategic policy, better medicines, and broad deployment can solve addiction at a population level, a goal that's seemed impossible for generations. CASPR is unlike any other organization, pursuing high-leverage approaches that can scale. Your support makes it possible.

From the New York Times coverage of CASPR's pilot program

Jessica Massarone from CASPR's GLP-1 for Addiction Program at OpenDoors — Photographed for the New York Times.

Give Online Today

Make an immediate impact in the fight against addiction by helping fund our research, programs, and advocacy efforts.

Donor Advised Funds

Your DAF can help make a lasting impact in curing addiction at scale.

Stock Gifts

Giving appreciated securities is one of the most tax-efficient ways to support our mission.

Cryptocurrency

We accept ETH and other major crypto assets.

Matching Gifts

CASPR is eligible for many employer matching programs.

To learn more about our work, or to discuss a transformational gift, please contact [email protected]. CASPR is a registered 501(c)(3) nonprofit organization, and donations are tax-deductible.

(Tax ID: 99-3967731)

Our Supporters

CASPR is funded by individuals and support from charitable foundations, both private and public. We do not accept funding from industry.

Coefficient Giving

A Lack of Innovation Has Stopped Progress on Addiction

Clinicians and scientists agree that addiction is a disease and we are facing a public health emergency. Despite these massive costs, innovation in treatment has lagged for decades.

49M+

Americans with a substance use disorder

$2T/yr

Annual cost of addiction to the U.S.

0.4%

Of the venture funding that cancer receives

FDA approvals in addiction medicine in 20 years — vs. 200+ in oncology

How CASPR Is Different

Existing medications for addiction are either lacking in efficacy or patient appeal, but this can change. CASPR is currently supporting the only two pilot projects in the world providing GLP-1RAs to real-world addiction programs, at Caron Treatment Center and OpenDoors in Rhode Island. Our work has been covered in the New York Times and many other national outlets.

We are a lean but very high-leverage organization, relentlessly focused on bringing a strategic approach to the field of addiction medicine and getting new treatments to patients as soon as possible. Our background is in startups, tech, science, and medicine — we are here to move fast, make change, and see impact.

What Your Investment Makes Possible

Funds real-world pilot programs in treatment centers, community settings, and under-studied populations that are often excluded from traditional research.
Powers studies that connect clinical outcomes to social outcomes like recidivism, employment, and long-term recovery stability.
Supports our innovative policy development work, moving governments at all levels towards strategic and scalable solutions to addiction.